Idioma:

Immuno-oncology in head and neck squamous cell carcinoma - a narrative review

Silva, A T da ; Silva, A C Simões E ; Petroianu, A

Brazilian journal of medical and biological research, 2023-01, Vol.56 (1), p.e12703-e12703 [Periódico revisado por pares]

Brazil: Associacao Brasileira de Divulgacao Cientifica (ABDC)

Texto completo disponível

Citações Citado por

Enviar para

Título:
Immuno-oncology in head and neck squamous cell carcinoma - a narrative review
Autor: Silva, A T da ; Silva, A C Simões E ; Petroianu, A
Assuntos: BIOLOGY ; Biomarkers ; Cancer ; Carcinoma, Squamous Cell - therapy ; Care and treatment ; Development and progression ; Head and neck ; Head and Neck Neoplasms - etiology ; Head and Neck Neoplasms - therapy ; Health aspects ; Humans ; Immune response ; Immuno-oncology ; Immunology ; Immunotherapy ; Immunotherapy - adverse effects ; Immunotherapy - methods ; MEDICINE, RESEARCH & EXPERIMENTAL ; Metastasis ; Quality of Life ; Review ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - therapy
É parte de: Brazilian journal of medical and biological research, 2023-01, Vol.56 (1), p.e12703-e12703
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: Immuno-oncology studies the immune system in cancer. In recent decades, immunotherapy has shown a good response to the treatment of various locally advanced and metastatic cancers. The main mechanisms of action include stimulation of the patient's own immune system to enhance immune responses acting in tumor escape pathways. This review examined the literature related to immune system mechanisms in head and neck squamous cell carcinoma (HNSCC) and their application in immunotherapy using biomarkers. The PUBMED, LILACS, MEDLINE, WHOLIS, and SCIELO databases were searched using the terms squamous cell carcinoma, head and neck, immuno-oncology, immunotherapy, and immunology. The main drugs currently available for clinical use in patients diagnosed with HNSCC include pembrolizumab and nivolumab, both classified as check-point inhibitors. These immunobiological agents improve patient survival and quality of life. Many authors and clinical trials point out that the recommendation of these agents is linked to the dose of PD-L1 (ligand expressed primarily by tumor cells), which proved to be an unreliable biomarker in the patient selection. Recommendation of immunotherapy depends on reliable biomarkers that must be identified in order to achieve good therapeutic results.
Editor: Brazil: Associacao Brasileira de Divulgacao Cientifica (ABDC)
Idioma: Inglês;Português

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Immuno-oncology in head and neck squamous cell carcinoma - a narrative review

Silva, A T da ; Silva, A C Simões E ; Petroianu, A

Brazil: Associacao Brasileira de Divulgacao Cientifica (ABDC)

Buscando em bases de dados remotas. Favor aguardar.